-
Axicabtagene ciloleucel, sold
under the
brand name Yescarta, is a
medication used for the
treatment for
large B-cell
lymphoma that has
failed conventional...
- B-cell
precursor acute lymphoblastic leukemia (B-ALL), and
axicabtagene ciloleucel (Yescarta),
marketed by Kite
Pharma originally for
diffuse large B-cell...
-
annual list of the
preceding year's 50
Smartest Companies.
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an
investigational therapy (for the treatment...
-
first 2
adoptive T-cell therapies,
tisagenlecleucel and
axicabtagene ciloleucel, were
approved by the FDA in 2017.
Another approach is
adoptive transfer...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
-
manufacturing process is expensive. Cost of
single infusions of
axicabtagene ciloleucel: US$373,000 Tisagenlecleucel: US$475,000 T cell
Efficacy of treatment...
-
trioxide Asparagine depleters (Asparaginase#/Pegaspargase)
Axicabtagene ciloleucel Belzutifan Bexarotene Brexucabtagene autoleucel Celecoxib Ciltacabtagene...
- the
United States. In October, a
similar therapy called axicabtagene ciloleucel was
approved for non-Hodgkin lymphoma. In October,
biophysicist and biohacker...
